Cybin Inc. to Present at Cantor Fitzgerald Health Conference
Ticker: HELP · Form: 6-K · Filed: May 29, 2024 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | May 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: conference-participation, healthcare, psychedelics
TL;DR
Cybin CEO speaking at Cantor Fitzgerald conference June 13th, webcast available.
AI Summary
Cybin Inc. filed a Form 6-K on May 29, 2024, announcing its participation in the Cantor Fitzgerald Health Conference on June 13, 2024. CEO Doug Drysdale is scheduled to present at 10:40 AM ET, discussing the company's progress in psychedelic-based therapeutics. The conference will be accessible via webcast.
Why It Matters
This presentation offers investors and the public an opportunity to hear directly from Cybin's CEO about their advancements in the psychedelic therapeutics sector, potentially influencing investor sentiment and stock performance.
Risk Assessment
Risk Level: low — This filing is a routine report of a company's participation in a conference, with no new material financial or operational information that would significantly alter risk.
Key Players & Entities
- Cybin Inc. (company) — Registrant
- Doug Drysdale (person) — CEO of Cybin Inc.
- Cantor Fitzgerald Health Conference (company) — Event
- June 13, 2024 (date) — Date of presentation
- 10:40 AM ET (time) — Time of presentation
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed by Cybin Inc. to report its participation in the Cantor Fitzgerald Health Conference and to provide a news release announcing this event.
When and where will Cybin Inc. be presenting?
Cybin Inc. will be presenting at the Cantor Fitzgerald Health Conference on June 13, 2024, at 10:40 AM ET.
Who will be presenting on behalf of Cybin Inc.?
Doug Drysdale, the Chief Executive Officer of Cybin Inc., will be presenting.
How can interested parties access the presentation?
The presentation will be accessible via a live audio webcast, with a link to be provided on Cybin's website.
What is the primary focus of Cybin Inc.'s business as indicated by this filing?
The filing indicates Cybin Inc. is involved in the pharmaceutical preparations sector, specifically focusing on psychedelic-based therapeutics, as it is presenting at a health conference.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-05-29 17:25:02
Filing Documents
- cybininc-form6xk05x29x2024.htm (6-K) — 11KB
- a05-29x2024icprprfinal.htm (EX-99.1) — 21KB
- image_0a.jpg (GRAPHIC) — 25KB
- 0001628280-24-025641.txt ( ) — 66KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date May 29, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated May 29, 2024